AIGEN Sciences

Executive Summary

AIGEN Sciences is a private, early-stage company that combines artificial intelligence and genomics to discover novel drug targets and therapeutics for complex diseases. Founded in 2021 and headquartered in New York, the company operates as a platform stage entity with 50–200 employees. By leveraging advanced machine learning algorithms on large-scale genomic datasets, AIGEN aims to identify high-value targets and accelerate the drug development pipeline, potentially reducing the time and cost associated with traditional discovery methods. While the company has not disclosed total funding or valuation, its focus on integrating AI with genomic data places it at the forefront of a rapidly growing sector within biopharma. As a platform-stage company operating in a competitive landscape, AIGEN Sciences faces challenges in validating its technology and securing partnerships or additional financing. The company has no publicly disclosed pipeline or FDA approvals, indicating it is likely still in preclinical or early research phases. However, the increasing demand for AI-driven drug discovery and the potential for collaborations with larger pharmaceutical players could provide significant upside. Conviction is moderate, given the lack of transparency on financials and progress, but the underlying technology and market trends suggest meaningful long-term potential if execution is successful.

Upcoming Catalysts (preview)

• Q4 2026Series B Funding Announcement70% success
• Q2 2027Major Pharmaceutical Partnership40% success
• Q3 2027Preclinical Proof-of-Concept Data Release50% success